Loading...
•
Sep 30, 2020
Alnylam Q3 2020 Earnings Report
Alnylam reported strong Q3 2020 results driven by the performance of ONPATTRO and GIVLAARI, as well as advancements in its late-stage pipeline.
Key Takeaways
Alnylam Pharmaceuticals reported a strong third quarter in 2020, with significant growth in ONPATTRO and GIVLAARI sales. The company is also expecting potential approval for OXLUMO and LEQVIO, which could further bolster growth. Alnylam is increasing its full-year revenue guidance for ONPATTRO.
ONPATTRO achieved global net product revenue of $82.5 million, with over 20% quarterly U.S. growth.
GIVLAARI achieved global net product revenue of $16.7 million.
Positive CHMP opinions received for OXLUMO and LEQVIO, potentially leading to four approved RNAi therapeutic medicines by year-end 2020.
Increased 2020 guidance range for ONPATTRO revenue from $280-$300 million to $295-$310 million.
Revenue by Segment
Forward Guidance
Alnylam updated its full year 2020 financial guidance, increasing the revenue expectations for ONPATTRO.
Positive Outlook
- ONPATTRO net product revenues are expected to be between $295 million and $310 million.
- Net revenues from collaborations are expected to be between $100 million and $150 million.
- GAAP R&D and SG&A expenses are expected to be between $1,160 million and $1,255 million.
- Non-GAAP R&D and SG&A expenses are expected to be between $1,000 million and $1,075 million.
- Strategic financing collaboration with Blackstone is expected to enable Alnylam to achieve a self-sustainable financial profile without need for future equity financings.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...